Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MT-3995 as Add-on Therapy to ACE-I or ARB in Type II Diabetic Nephropathy Subjects with Albuminuria and an eGFR ≥60 mL/min/1.73m2

Next Previous
X
Search
Trial Profile

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MT-3995 as Add-on Therapy to ACE-I or ARB in Type II Diabetic Nephropathy Subjects with Albuminuria and an eGFR ≥60 mL/min/1.73m2

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apararenone (Primary) ; ACE inhibitors; Angiotensin receptor antagonists
  • Indications Diabetic nephropathies; Hypertension
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Mitsubishi Tanabe Pharma Corporation

    • Most Recent Events

    • 08 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2014 Planned End Date changed from 1 Dec 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 25 Sep 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top